Focused On-demand Library for Gamma-glutamyl hydrolase

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q92820

UPID:

GGH_HUMAN

Alternative names:

Conjugase; GH; Gamma-Glu-X carboxypeptidase

Alternative UPACC:

Q92820

Background:

Gamma-glutamyl hydrolase, known alternatively as Conjugase, GH, and Gamma-Glu-X carboxypeptidase, plays a crucial role in the metabolism of pteroylpolyglutamates. It hydrolyzes the polyglutamate sidechains of these compounds, progressively removing gamma-glutamyl residues to yield folic acid and free glutamate. This enzymatic activity is essential for the bioavailability of dietary pteroylpolyglutamates and the metabolism of antifolates.

Therapeutic significance:

Understanding the role of Gamma-glutamyl hydrolase could open doors to potential therapeutic strategies. Its pivotal function in the metabolism of folates and antifolates highlights its importance in nutritional science and pharmacology, suggesting avenues for intervention in diseases where folate metabolism is implicated.